- Conditions
- Healthy Volunteers
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Anaheim, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Garadacimab, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 19 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
- Conditions
- Healthy Participants
- Interventions
- CSL312
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Hereditary Angioedema
- Interventions
- Garadacimab
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
- Conditions
- Hereditary Angioedema
- Interventions
- Factor XIIa antagonist monoclonal antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more